Replies to post #179534 on Avid Bioservices Inc (CDMO)

[revenue_monster]

Bio. You have pieces of 600 puzzles that will never fit together

[biopharm]

..the more I keep seeing pieces of the puzzle that fall back to BMS, I think I may have to decrease my chances that CALICO and Art Levinson are being welcomed at the door with a fistful of dollars

One last speculation... is if it is BMS, then Bavi just may be heading into the diabetes area, which fits the reason why BMS needed a bit more money and unloaded everything to AZ:

The companies said they anticipate “substantially all” 4,100 of BMS’ diabetes employees, including former Amylin staffers, will be transferred to AZ, though “a number” of R&D and manufacturing employees dedicated to diabetes will remain with BMS.

http://www.genengnews.com/gen-news-highlights/bms-sells-diabetes-business-to-astrazeneca-for-up-to-4b/81249274/

--------------------------------------

Pay attention to Mark G. Foletta -ex Amylin and Jeffrey S. Hatfield - ex BMS ... but both most recent BOD at Ambit and of course this post is fed off of all the previous Tom Sklenar posts. ( employeed with Peregrine and Ambit Biosciences ).

Peregrine/Ambit collaboration now reaching 6 months....

http://www.linkedin.com/pub/tom-sklenar/29/772/899

-----------------------------------

San Diego-based biopharmaceuticals company Ambit Biosciences has shuffled its board this morning, saying it has added Jeffrey S. Hatfield as a member of its board of directors, as current board member Steven Elms resigns. Hatfield is the CEO and is on the baord of Vitae Pharmaceuticals, and also has served at Bristol-Myers Squibb. The company did not say why Elms resigned, but said Hatfield is a direct replacement for Elms in that position. Ambit is focused on oncology, autoimmune and inflammatory diseases.

http://www.socaltech.com/ambit_biosciences_shuffles_board/s-0055357.html